Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression by DeNardo, David G & Coussens, Lisa M
Page 1 of 10
(page number not for citation purposes)
Available online http://breast-cancer-research.com/content/9/4/212
Abstract
Recent insights into the molecular and cellular mechanisms under-
lying cancer  development have revealed that immune cells func-
tionally regulate epithelial cancer development and progression.
Moreover, accumulated clinical and experimental data indicate that
the outcome of an immune response toward an evolving breast
neoplasm is largely determined by the type of immune response
elicited. Acute tumor-directed immune responses involving cyto-
lytic T lymphocytes appear to protect against tumor development,
whereas immune responses involving chronic activation of humoral
immunity, infiltration by Th2 cells, and protumor-polarized innate
inflammatory cells result in the promotion of tumor development
and disease progression. Herein we review this body of literature
and summarize important new findings revealing the paradoxical
role of innate and adaptive leukocytes as regulators of breast
carcinogenesis.
Introduction
Breast cancer is the most frequent malignant tumor of
women in North America [1]. Standard treatment modalities
have improved the overall outlook and quality of life for
women with breast cancer; however, the fact that 40% still
succumb to disease highlights the need for new therapeutic
approaches and identification of new therapeutic targets.
While genetic and epigenetic changes in genes that regulate
mammary epithelial cell proliferation, survival, polarity and/or
differentiation are probable ‘initiators’ of breast carcino-
genesis, several lines of evidence indicate that stromal cell
responses in premalignant mammary tissue may ‘promote’
progression to cancer and/or the metastatic capability of
malignant mammary epithelial cells. Cellular components of
tumor stroma include (myo)fibroblasts, vascular cells,
infiltrating leukocytes and specialized mesenchymal support
cells unique to each tissue microenvironment. A growing
body of evidence has recently implicated tumor-infiltrating
leukocytes as causal players in cancer development [2-8].
The present review focuses on the paradoxical roles of innate
and adaptive leukocytes as regulators of breast carcino-
genesis, and highlights recent experimental data indicating
that therapeutically targeting these diverse immune cell types
by either neutralizing and/or bolstering their specific
bioactivities may provide a therapeutic advantage to patients
with breast cancer.
Leukocytes and carcinoma development
Leukocytes represent a diverse assortment of immune cells
composed of both innate (myeloid) and adaptive (lymphoid)
lineages. Innate immune cells, including macrophages,
granulocytes, mast cells, dendritic cells (DCs), and natural
killer (NK) cells, represent the first line of defense against
pathogens and foreign agents. When tissue homeostasis is
perturbed, tissue-resident macrophages and mast cells
locally secrete soluble factors such as cytokines, chemo-
kines, bioactive mediators, and matrix-remodeling proteins
that recruit additional leukocytes from the circulation into
damaged tissue (that is, inflammation) [3,9,10]. Recruited
innate immune cells can directly eliminate pathogenic agents
in situ. At the same time, DCs take up foreign antigens
(including tumor antigens) and migrate to lymphoid organs,
where they present their antigens to adaptive immune cells.
Upon recognition of foreign antigen presented by DCs or
other professional antigen-presenting cells, adaptive immune
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cells, such as T lymphocytes or B lymphocytes, undergo
clonal expansion in order to mount an ’adaptive’ response
targeted against the foreign agent [11,12]. Acute activation
of innate immunity therefore sets the stage for activation of
more sophisticated, antigenically committed, adaptive immune
responses. Once foreign agents have been eliminated,
inflammation resolves and tissue homeostasis is restored.
The inflammatory responses necessary for enabling an
immune reaction may, however, also set the stage for
promoting neoplastic disease. As early as 1863, Virchow first
postulated that cancer originates at sites of chronic inflam-
mation, in part based on his hypothesis that some classes of
irritants causing inflammation also enhance cell proliferation
[13]. When tissues are injured or are exposed to chemical
irritants, damaged cells are removed by the induction of cell
death pathways, while cell proliferation is enhanced to
facilitate tissue regeneration in an attempt to re-establish
tissue homeostasis. Proliferation and inflammation resolve
only after insulting agents are removed or tissue repair is
completed. In contrast, when insulting agents persist over
time, sustained cycles of cell proliferation and death in
environments rich in inflammatory cells and their bioactive
products may increase neoplastic risk and foster tumor
progression [3]. While sporadic or inherited genetic
mutations in critical genes regulating cell cycle, programmed
cell death, differentiation and adhesion may represent
initiating events in tumorigenesis (‘initiation’), chronic inflam-
mation favors selection of additional features in initiated cells
that may promote their full malignant transition (’promotion’).
Historically, leukocytes found in and around developing
tumors were thought to represent an attempt by the host to
eradicate transformed neoplastic cells. Certain leukocytes,
such as cytotoxic T lymphocytes (CTLs) and NK cells,
undeniably play a vital function in constraining tumor
development [14], and as such it has been postulated that
many more neoplasms arise than those that eventually
develop to fully malignant disease. Epidemiologic data
support this contention, as evidenced by the increased
incidence of viral-associated cancers [15], including human
papillomavirus-related cervical and squamous carcinoma,
herpesvirus-8-associated Kaposi’s sarcoma and Epstein–Barr
virus-related non-Hodgkin’s lymphoma in immunocompro-
mised individuals [15-19]. Similar to viral-associated cancers,
there are data revealing an increased incidence of
carcinogen-associated cancers in immune-compromised
populations, including melanoma and lung adenocarcinoma
[17,20]. Where carcinogen exposure and pathogen exposure
are not thought to be etiologic factors, however, immune-
compromised women exhibit reduced relative risk for
common epithelial cancers, including breast adenocarcinoma
[17,20-23]. Together, these epidemiological studies indicate
that the overall risk for, and development of, (breast) cancer
may, in part, be regulated by the immune status of the
individual.
Adaptive immunity and carcinoma
development: a role for B lymphocytes
A growing body of literature has emerged demonstrating that
leukocytes functionally contribute to the development of most
human solid tumors. Leukocytic infiltrates into the neoplastic
stroma increase, paralleling breast tumorigenesis (Figures 1
and 2). Profiles of these immune cells vary but, in general,
include both lymphoid and myeloid lineages.
B lymphocytes are recognized as contributing to anticancer
immune responses via their secretion of antigen-specific
immunoglobulins. While it is clear that acute activation of B
cells may play a role in eradicating early neoplastic cells, or
may participate in spontaneous regression of tumors through
classical and well-studied immunoglobulin-mediated mecha-
nisms, recent data also indicate that chronic activation of B
cells may paradoxically play a role in potentiating carcinoma
development (Figure 3).
B-cell precursors mature within bone marrow, where somatic
recombination of immunoglobulin genes results in expression
of a diverse array of B-cell receptors. Mature antigen-commit-
ted B cells migrate to secondary lymphoid organs (lymph
nodes or spleen, predominantly). Upon antigen recognition by
B-cell receptors, the B lymphocytes become activated and
undergo clonal expansion, resulting in their enhanced capacity
to recognize foreign antigens [24]. Acute activation of B-
lymphocyte responses (to foreign antigens or tissue damage)
can also result in rapid induction of several soluble mediators,
including diverse immunoglobulin subtypes, B-cell-derived
cytokines such as IL-6 and activation of complement
cascades, which together trigger recruitment of innate
immune cells from the circulation. In this manner, acutely
activated B cells orchestrate phagocytic or cytotoxic
destruction of immunoglobulin-complexed antigens (patho-
gens or damaged cells) by innate immune cells. Such acute B-
cell responses are critical for protecting tissues from patho-
gens and nonself-antigens. Chronic activation of B cells can
be deleterious, however, as evidenced by their association
with several pathologic disease states (rheumatoid arthritis
and other autoimmune diseases) and some cancer types [25].
During breast carcinogenesis, mature B cells (including naive
cells and activated cells) can be found in secondary lymphoid
tissues as well as in tumor-associated stroma (Figure 2). As
compared with healthy patients without evidence of cancer,
the sentinel (draining) lymph nodes of breast cancer patients
contain enriched populations of proliferating and affinity
matured (IgG+) B lymphocytes [26]. Moreover, data from
retrospective studies examining the percentages of B cells
present in sentinel and auxiliary lymph nodes of breast cancer
patients reveal that their presence and/or maturation (IgG+)
correlates with increases in disease stage (stage I versus
stage II) and in total tumor burden [27,28]. Urdiales-Viedma
and colleagues utilized immunohistochemical detection of
IgA, IgG and IgM in axillary lymph nodes from 50 unselectedPage 3 of 10
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ductal breast carcinomas, and found that lymph nodes with
IgG+ lymphoid follicles and/or metastatic lymph nodes with
IgM+ lymphoid cells were statistically related to breast tumors
of high histologic grade and more than three lymph node
metastases [29].
Similarly, B cells present in breast tumor-associated stroma
may also play a role in disease progression. Several studies
have reported that infiltrating B lymphocytes represent the
predominant lymphocytic population (in excess of T lympho-
cytes) in premalignant breast tissue, including hyperplasia
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Figure 1
Development of human breast carcinoma is characterized by abundant infiltration of immune cells. Representative sections of normal, premalignant,
and malignant human breast tissue stained with hematoxylin and eosin (H&E) (upper panels), and following immunodetection of CD45 (leukocyte
common antigen, brown staining). DCIS, ductal carcinoma in situ.
Figure 2
Development of human breast carcinoma is characterized by abundant infiltration of lymphocytes into neoplastic tissue. Representative sections of
normal, premalignant, and malignant breast assessed for the presence of CD4+ (upper panels) and CD8+ (middle panels) T lymphocytes (brown
staining in panels), as well as CD20+ B lymphocytes (red staining in lower panels), demonstrating the extent of immune-cell infiltration into
premalignant and malignant stroma. DCIS, ductal carcinoma in situ.and early ductal carcinoma in situ (DCIS) [30,31] (Figure 2).
Approximately 20% of invasive breast cancers contain high
numbers of B cells; when present, these cells can comprise
up to 60% of the neoplasia-associated lymphocyte
population [32]. These observations are not specific to breast
cancer – 70% of solid tumors contain elevated populations of
B cells [33]. Although the presence of chronically activated
B cells in breast cancer patients is clear, how these cells
might be effecting disease progression has not been
established. In DCIS and invasive carcinoma, tumor-
associated B cells are typically found in perivascular locales
clustering in aggregates with T cells, forming ectopic follicles
[32,34,35]. These follicles contain B cells interdigitated
around CD21+ follicular DCs, thus identifying them as
authentic ectopic follicles. Formation of ectopic follicles
containing mature plasma cells indicates that the presence of
B cells in neoplastic mammary tissue is the result of chronic
activation rather than nonspecific chemoattraction. Extra-
nodal B-cell proliferation and ectopic follicle formation have
also been described in several autoimmune diseases
(rheumatoid arthritis, multiple sclerosis, Sjogren’s disease
and Graves disease), where they are thought to underlie the
disease pathogenesis [36-39].
How might B lymphocytes regulate carcinoma development?
A vast literature exists describing the occurrence of (auto)-
antibodies in either the serum of cancer patients or in
interstitial antibody deposition in tumors [40]. An early
presence of autoantibodies (in particular, antinuclear anti-
bodies and smooth muscle antibodies) in serum of cancer
patients is well known to correlate with an unfavorable
prognosis [41]. Approximately 50% of breast cancer patients
contain circulating immunoglobulins that specifically react
with tumor-derived antigens – autoantibodies against
ErbB2/HER2/neu are present in 20% of patients with ErbB2-
positive breast cancer, making it the most common breast
cancer ‘autoantigen’ [42]. Paradoxically, the presence of
specific autoantibodies in serum and/or at tumor sites
correlates with poor patient survival [40,41,43] – perhaps
indicating that immunoglobulins resulting from chronic B-cell
activation in response to tumor-specific antigens might
promote disease progression (Figure 3).
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Figure 3
Contrasting roles of adaptive leukocytes during cancer development. During acute inflammatory responses (left panel), Th1 CD4+ and CD8+
T cells directly regulate tumor cell cytotoxicity, while indirectly polarizing innate immune cells toward tumor suppression (such as M1 polarization of
tumor-associated macrophages [TAMs]). B-cell-derived factors (immunoglobulins and complement) facilitate recruitment of innate leukocytes and
targeted destruction of neoplastic cells. During chronic inflammation, however (right panel), myeloid suppressor cells, Th2 CD4+ T cells and
regulatory T (T-reg) cells function in combination to both repress CD8+ cytotoxicity and to induce protumoral polarization of innate immune
response (such as M2 polarization of TAMs) via cytokine secretion (IL-4, IL-13, IL-10, IL-6 and transforming growth factor beta (TGFβ)). Chronically
activated B cells promote accumulation of innate cells in the neoplastic stroma by immunoglobulin and cytokine production. When polarized, as
during chronic inflammation, these innate immune cells in turn provide a rich proangiogenic and protumoral microenvironment. CTL, cytotoxic
T lymphocyte; FcR, Fc receptor; INF, interferon; SC, suppressor cells; VEGF, vascular endothelial growth factor.Despite the presence of antitumor antibodies in greater than
one-half of all breast cancer patients, there are only few
reports of spontaneous tumor regression (presumed to be
immunologic) in the absence of therapy [44,45]. Several
factors may influence the efficiency of antitumor antibodies in
inducing tumor regression/destruction, including the immuno-
globulin concentration, HLA expression, tumor tolerance/
immune suppression, and impaired cytotoxic T-cell activity.
Whether individuals with progressing tumors harbor a higher
antigen load that thus triggers enhanced immunoglobulin
production, or whether an increased presence of serum or
interstitial immunoglobulins predisposes patients to
development of more advanced or recurrent cancers,
therefore requires further study. While the answer is not
clear, the combined implication of the data is that B lympho-
cytes do play a role in human carcinoma development,
therefore necessitating a mechanistic evaluation of their role
and specificity to determine whether they represent tractable
targets for anticancer therapy.
Adaptive immunity and carcinoma
development: a role for T lymphocytes
Histochemical detection of T lymphocytes in archival human
carcinoma tissues has revealed that they also are commonly
associated with developing carcinomas (Figure 2); however,
the prognostic significance of T-cell infiltrations during breast
carcinogenesis is subject to great debate. While B cells
appear to represent the predominant lymphocyte during early
breast cancer progression [34], infiltrating T lymphocytes
(both CD4+ and CD8+) are more extensive in higher grade
DCIS and invasive carcinomas [46].
The extent of T-cell infiltration into invasive breast carcinomas
has been reported to range from 1% to 45% of the total
cellular mass [47]. In rapidly proliferating tumors, the
presence of T lymphocytes (by histopathological determina-
tion) at tumor sites is a good prognostic indicator when
compared with nonimmunogenic tumors, and correlates with
auxillary lymph node negativity, a smaller tumor diameter, a
lower histological grade and recurrence-free survival [48] –
therefore supporting an overall role for T cells in immune
surveillance. The exact composition of T lymphocyte infiltra-
tion varies greatly, however, and may profoundly affect disease
progression and overall patient survival.
During breast carcinogenesis, the presence of metastatic
mammary epithelial cells in sentinel lymph nodes draining the
primary tumor represents the strongest prognostic indicator
for disease progression and overall patient outcome [49-51].
While it is unclear whether the presence of CD8+ CTLs alone
provides any prognostic information, the presence of high
percentages of CD4+ T-helper cells at primary tumor sites
positively correlates with disease progression, including
metastatic spread to sentinel lymph nodes and increased
primary tumor size [47,52]. Perhaps more significant is the
ratio of CD4+ to CD8+ cells, where primary tumors with ratios
greater than one correlate with lymph node metastasis and
reduced patient survival [47,52]. Similar results have been
reported for colorectal carcinoma [53], renal carcinoma,
esophageal carcinoma, and small-cell lung carcinoma [54].
Why are CD8+ CTL-mediated responses not more effective
in eradicating or minimizing cancer occurrence and how
might CD4+ T cells be involved in enhancing breast cancer
progression? One plausible mechanism may have to do with
the ’polarity’ of the CD4+ T-helper-cell response at primary
tumor sites and/or their distant metastases (Figure 3). CD4+
T-helper cells are activated in response to soluble factors and
can be classified generally into two categories as either Th1
cells or Th2 cells (Figure 4) [55]. Following an activating
stimulus, CD4+ T-helper cells that are Th1-polarized secrete
IFNγ, transforming growth factor beta, TNFα and IL-2 [56].
These cytokines collaborate with the cytotoxic/cell killing
functions of CD8+ T cells [57] and can induce upregulation
of antigen processing (in the proteasome), can induce
expression of MHC class I and II molecules, and can induce
other antigen display cofactors in neoplastic cells. Th1 CD4+
T-helper cells also enhance antitumor immune responses by
secretion of INFγ, which in turn induces activation of
macrophage cytotoxic activity [58]. In contrast Th2-polarized
CD4+ T-helper cells express IL-4, IL-5, IL-6, IL-10 and IL-13,
which induce T-cell anergy and loss of T-cell-mediated
cytotoxicity while also enhancing humoral immunity (B-cell
function) [59]. Taken together, Th1 responses are thought to
be beneficial toward antitumor immunity [60-63] whereas
Th2 responses may downregulate cell-mediated antitumor
immunity [63-67] and enhance protumor humoral responses
[68,69].
Role for regulatory T lymphocytes
In addition to T-helper-cell polarity, developing neoplasms
can escape CD8+ T-cell cytotoxicity by promoting expansion
of regulatory T cells (Treg). Treg cells normally function to
protect tissue from autoimmune disease by suppressing self-
reactive cells. Typically characterized by expression of CD4,
CD25 and FOXP3, Treg cells can account for approximately
5–10% of all T lymphocytes in healthy tissues.
In breast cancers the percentage of Treg cells, as assessed by
FOXP3 positivity, increases in parallel with the disease stage,
from normal to DCIS and from DCIS to invasive carcinoma
[70]. In patients with invasive carcinoma the presence of high
numbers of FOXP3+ T cells predicts worse relapse-free
survival and decreased overall patient survival [70], and may
indicate that the presence of Treg cells promotes tumor
progression by inhibiting immunosuppression. The mecha-
nisms underlying immunosuppression are not clear; however,
CD4+CD25highFOXP3+ Treg cells retain the ability to actively
inhibit CD4+CD25– T cells, CD8+ T cells, DCs, NK cells, and
B cells in a cell-to-cell contact and dose-dependent manner
[71-75]. The mechanisms by which developing tumors might
stimulate proliferation and differentiation of Treg lymphocytes
Available online http://breast-cancer-research.com/content/9/4/212
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tumor cells and of CCL22 by tumor-associated macrophages
may act as chemotactic and differentiation agents for Treg
cells [76-79].
Acquired immunity and carcinoma
development
It is well established that chronic infiltration of tissue by some
innate immune cell types (for example, immature monocytes,
macrophages, mast cells or neutrophils) contributes to
epithelial cancer development [3,8,80]. Many studies have
reported that inflammatory leukocytes promote cancer develop-
ment due to their enormous plasticity and their capacity to
produce a myriad of cytokines, chemokines, metalloserine
and metallocysteine proteases, reactive oxygen species,
histamine and other bioactive mediators [3,8,80]. Several
physiological processes necessary for tumor development,
such as enhanced cell survival, tissue remodeling,
angiogenesis and suppression of antitumor adaptive immune
responses, are thus regulated by leukocytic infiltrates in
neoplastic environments. This regulation is exemplified by
positive correlations between numbers of innate immune cells
(macrophages, mast cells and neutrophils) infiltrating human
tumors with the number of blood vessels [81,82], and by
experimental findings in mouse models where attenuating
innate immune cell infiltration of premalignant tissue reduces
angiogenesis and limits tumor development [83-90].
The earliest reports revealing a potential tumor-enhancing
effect of adaptive immunity found that passive transfer of
tumor-specific antibodies enhanced in vivo outgrowth of
transplanted tumor cells or chemically induced tumors
[91-93]. More recently, the availability of de novo
carcinogenesis mouse models for the study organ specific
cancer development has allowed experimentalist to revisit
these analysis. Their experiments have revealed that the
tumor enhancing roles of humoral immunity are more involved
in innate immune cell responses, as opposed to direct
regulation of neoplastic cell survival. For example, active
immunization of mice harboring a mutant ras oncogene
resulted in activation of humoral immune responses and
enhanced papilloma formation upon chemical promotion
[94,95].
Studies by Barbera-Guillem and colleagues reported that
‘antitumor’ humoral immune responses potentate in vivo
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Figure 4
Model depicting the consequences of acute inflammation versus chronic inflammation. During acute antitumor inflammatory responses (left panel),
Th1-polarized T cells secrete antitumor cytokines (IL-2 and INFγ, for example), which in combination with antitumor-directed B-cell-derived factors
(such as immunoglobulins (Igs)) activate tumor inhibitory responses in recruited innate immune cells and cytotoxic T lymophocytes (CTLs) that
together favor tumor rejection. In contrast, chronic activation of immune response (right panel) without resolution (of damage) often results in
accumulation of regulatory T (Treg) cells, Th2 cells, and activated B cells, which in turn secrete progrowth factors (IL-4, IL-6, IL-10, IL-13,
transforming growth factor beta (TGFβ) and immunoglobulins, for example) that enhance protumor responses in innate immune cells and inactivate
CTL cytotoxicity, thus favoring tumor promotion.growth and invasion of injected murine and human tumor cell
lines via recruitment and activation of protumor granulocytes
and macrophages [94,96,97]. Once in the neoplastic
microenvironment, deposited immunoglobulin may mediate
recruitment of innate immune cells via activation of comple-
ment cascades or engagement with Fc receptors expressed
on resident or recruited innate immune cells that trigger
various cellular responses, including phagocytosis, antigen
presentation, secretion of proinflammatory mediators and
antibody-dependent cytotoxicity [98,99]. During breast cancer
development, immunoglobulin deposition in neoplastic stroma
is known to increase the bioavailability of vascular endothelial
growth factor (VEGF) by binding to Fc receptors on tumor-
associated macrophages, thus triggering release of VEGF
into the interstitium [96]. Moreover, the presence of
endocytosed immunoglobulin in macrophages in breast
carcinoma tissues corresponds with local extracellular VEGF
protein levels and local angiogenic vascular buds [96].
The significance of tumor-associated macrophages has been
experimentally addressed in a mouse model of mammary
carcinogenesis; that is, mouse mammary tumor virus–
polyomavirus middle T antigen transgenic mice [86]. In this
model of mammary carcinogenesis, infiltration of macro-
phages into premalignant mammary tissue is associated with
tumor progression [100]. Failure to recruit macrophages into
neoplastic tissue does not alter the hallmarks of
premalignancy, but instead significantly delays development
of invasive carcinomas and results in reduced pulmonary
metastases [86]. Metastatic potential is restored by
transgenic expression of colony-stimulating factor (CSF)-1 in
the mammary epithelium of CSF-1-deficient/polyomavirus
middle T antigen mice [86]. Macrophage stimulation of
mammary tumor progression is at least in part due to their
ability to enhance angiogenesis via regulating VEGF levels
and bioavailability [101]. These experimental data combined
with the positive correlation between CSF-1 levels,
macrophage recruitment and poor prognosis in human
cancers [102] support the notion that macrophages and/or
their products play a major role in facilitating late-stage
metastatic progression of tumors [86]. Other cells of myeloid
lineage have also been reported to contribute to tumor
development – NK cells can play a role in protection against
experimental tumor growth, in part by producing mediators
with antiangiogenic properties [103,104]. These studies have
together induced a paradigm shift regarding the role of
immune cells during malignant progression. Whereas the
historical viewpoint suggested that host immunity is
protective with regards to cancer, it is now clear that certain
subsets of chronically activated innate immune cells promote
growth and/or facilitate survival of neoplastic cells.
In addition to providing a survival advantage to evolving
neoplastic cells through their release of protumor mediators,
is there evidence that recruited innate immune cells regulate
any antitumor bioactivities of T cells present in premalignant/
malignant mammary tissue? Neoplastic microenvironments
favor polarized chronic protumorigenic inflammatory states,
as opposed to those representing acute antitumor immune
responses [8,105]. Clinical data indicate that the ‘immune
status’ of healthy individuals is distinct as compared with
those harboring malignant tumors, where T lymphocytes in
the later population are found to be functionally impaired
[106]. A subset of innate immune cells (for example, myeloid
suppressor CD11b+Gr-1+ cells) accumulate in the peripheral
blood of cancer patients [107,108], as well as in tumors and
lymphoid organs [105,108,109]. Myeloid suppressor cells
are known to induce T-lymphocyte dysfunction by direct
cell–cell contact and by production of immunosuppressive
mediators, and thus actively inhibit antitumor adaptive
immunity [108,109]. Myeloid suppressor cells can also
directly promote tumor growth by contributing to tumor-
associated angiogenesis [110]. In addition, malignant lesions
attract regulatory T cells that can suppress effector functions
of CTLs [105]. Immune states such as these disable tumor-
killing CD8+ CTL responses and enable states of immune
privilege that foster escape from antitumor immunity while
simultaneously exploiting activated innate immune cells that
enhance cancer development. The degree to which similar
mechanisms are at play during breast carcinogenesis is
currently being investigated.
Cytokines derived from activated humoral immunity and/or
Th2 T lymphocytes also actively regulate chemoattraction and
polarization of tumor-associated leukocytes, especially
macrophages. Chronically activated B cells (typically in
germinal centers or in ectopic follicles) can produce
granulocyte–macrophage-CSF, TNFα, IL-6, and IL-10 [111].
These cytokines, in combination with Th2 cytokines such as
IL-4, IL-13, and IL-10, are potent effectors of innate immune
cell polarization. Protumor M2 polarization in macrophages is
induced by the Th2/humoral cytokines IL-4 and IL-10, while
simultaneously repressing antitumor M1 macrophage polariza-
tion [112]. Granulocyte–macrophage-CSF, IL-6 and IL-10
secreted by activated B cells suppress macrophage cytotoxic
activity [112], while IL-10 inhibits both antigen presentation
by macrophages as well as monocyte differentiation into DC
lineages [113]. Taken together, factors derived from
chronically activated lymphocytes sculpt innate immune cell
responses towards tumor tolerance and promotion of disease
progression.
Conclusions
During the past decade, insights have been gained regarding
mechanisms underlying the dynamic interplay between
immune cells and tumor progression. The accumulated data
indicate that the outcome of an immune response toward a
tumor is largely determined by the type of immune response
elicited (Figure 3). A tumor-directed immune response involv-
ing cytolytic CD8+ T cells, Th1 cells and NK cells appears to
protect against tumor development and progression. If, on the
other hand, the immune response involves B cells and
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response the probable outcome is promotion of tumor
development and progression. This balance between a
protective cytotoxic response and a harmful humoral or Th2
response can be regulated systemically by the general
immune status of the individual, as well as locally by myeloid
suppressor cells and Treg cells, and thus offers clinicians
attractive targets for anticancer immune-based therapies.
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